• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高胆固醇血症及其他血脂异常工作组建议的基本原理与概述:中期报告。加拿大卫生部血脂异常工作组

Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada.

作者信息

Frohlich J, Fodor G, McPherson R, Genest J, Langner N

机构信息

Healthy Heart Program, St Paul's Hospital, Vancouver, British Columbia.

出版信息

Can J Cardiol. 1998 Apr;14 Suppl A:17A-21A.

PMID:9594929
Abstract

A panel consisting of lipidologists, epidemiologists, cardiologists, internists, general practitioners, and public health and government representatives used the evidence-based approach to examine the rationale for a draft of recommendations for medical management of lipid disorders. The proposed recommendations deal with assessment of cardiovascular risk based on history, physical examination and laboratory findings; assessment of the fasting lipid profile; diagnosis and treatment of secondary risk factors; calculation of the 10-year risk of a cardiac event; initiation of lifestyle modifications in patients in whom low density lipoprotein cholesterol (LDL-C), total:high density lipoprotein cholesterol (HDL-C) ratio or triglycerides exceeds target values based on a patient's risk category; follow-up; treatment with drugs; and choices of drugs. In contrast to previous recommendations, there are new, considerably lower, cholesterol level targets for secondary prevention, with a less important emphasis on total cholesterol value than on LDL-C or total:HDL-C ratio and triglyceride levels, and an emphasis on determining the likelihood of a cardiac event by evaluating all relevant risk factors and sharpening the focus on nondrug treatment, which should result in treating a greater percentage of at-risk patients.

摘要

一个由脂质学家、流行病学家、心脏病学家、内科医生、全科医生以及公共卫生和政府代表组成的小组采用循证方法,审视了脂质异常疾病医学管理建议草案的依据。拟议的建议涉及基于病史、体格检查和实验室检查结果评估心血管风险;评估空腹血脂谱;诊断和治疗次要危险因素;计算心脏事件的10年风险;对于低密度脂蛋白胆固醇(LDL-C)、总胆固醇与高密度脂蛋白胆固醇(HDL-C)之比或甘油三酯超过基于患者风险类别设定的目标值的患者,启动生活方式改变;随访;药物治疗;以及药物选择。与先前的建议相比,二级预防有了新的、显著更低的胆固醇水平目标,对总胆固醇值的重视程度低于对LDL-C或总胆固醇与HDL-C之比及甘油三酯水平的重视程度,并且强调通过评估所有相关危险因素来确定心脏事件的可能性,并更加注重非药物治疗,这应该会使更大比例的高危患者得到治疗。

相似文献

1
Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada.高胆固醇血症及其他血脂异常工作组建议的基本原理与概述:中期报告。加拿大卫生部血脂异常工作组
Can J Cardiol. 1998 Apr;14 Suppl A:17A-21A.
2
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.阿托伐他汀治疗对有心血管风险的2型糖尿病患者的长期(18个月)疗效。
Nutr Metab Cardiovasc Dis. 2002 Feb;12(1):29-35.
3
Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.以高密度脂蛋白胆固醇水平低为特征的人群中血脂异常的风险判定
Am Heart J. 2003 Dec;146(6):1052-9. doi: 10.1016/S0002-8703(03)00516-7.
4
Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.法国全科医疗中接受降脂治疗患者的混合性血脂异常:一项观察性研究。
Clin Ther. 2007 Aug;29(8):1671-81. doi: 10.1016/j.clinthera.2007.08.003.
5
Rising to the challenge of the new NCEP ATP III guidelines: exceeding current therapeutic limitations.迎接新的美国国家胆固醇教育计划成人治疗组第三次报告(NCEP ATP III)指南的挑战:突破当前治疗局限。
Am J Manag Care. 2002 Feb;8(2 Suppl):S23-8; discussion S45-7.
6
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.一项为期52周的随机、开放标签、平行组比较研究,旨在观察匹伐他汀和阿托伐他汀对日本低密度脂蛋白胆固醇水平升高且伴有糖耐量异常患者的高密度脂蛋白胆固醇水平及糖代谢的耐受性和影响。
Clin Ther. 2008 Jun;30(6):1089-101. doi: 10.1016/j.clinthera.2008.05.017.
7
Lipid management with statins. The lower the better?使用他汀类药物进行血脂管理。越低越好?
Z Kardiol. 2004 Jan;93(1):4-9. doi: 10.1007/s00392-004-1023-y.
8
Niacin-based therapy for dyslipidemia: past evidence and future advances.基于烟酸的血脂异常治疗:过去的证据与未来的进展
Am J Manag Care. 2002 Sep;8(12 Suppl):S315-22.
9
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗专家组第三次指南的影响。
J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001.
10
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗专家组第三次指南的影响。
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. doi: 10.1161/01.ATV.0000133317.49796.0E.

引用本文的文献

1
Atherogenic index of plasma as a marker of cardiovascular risk factors in Mexicans aged 18 to 22 years.血浆致动脉粥样硬化指数作为18至22岁墨西哥人心血管危险因素的标志物。
Proc (Bayl Univ Med Cent). 2020 Aug 21;34(1):22-27. doi: 10.1080/08998280.2020.1799479.
2
Prediction of cholesterol ratios within a Korean population.韩国人群胆固醇比率的预测。
R Soc Open Sci. 2018 Jan 17;5(1):171204. doi: 10.1098/rsos.171204. eCollection 2018 Jan.
3
Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.
影响英国全科医疗中开具降血脂药物用于心血管疾病一级预防处方的患者因素:一项全国性回顾性队列研究。
PLoS One. 2013 Jul 26;8(7):e67611. doi: 10.1371/journal.pone.0067611. Print 2013.
4
The importance of local criteria in the diagnosis of metabolic syndrome in Saudi Arabia.在沙特阿拉伯,局部标准在代谢综合征诊断中的重要性。
Ther Adv Endocrinol Metab. 2013 Apr;4(2):51-9. doi: 10.1177/2042018813483165.
5
Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh.来自安得拉邦的健康南印度人的血清总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、甘油三酯、脂蛋白(a)、载脂蛋白A-I、A-II、B、C-II、C-III和E的参考区间。
Indian J Clin Biochem. 2009 Oct;24(4):343-55. doi: 10.1007/s12291-009-0063-5. Epub 2009 Dec 30.
6
Statin wars following coronary revascularization - evidence-based clinical practice?冠状动脉血运重建后的他汀类药物之争——基于证据的临床实践?
Can J Cardiol. 2007 Mar 15;23(4):319; author reply 319. doi: 10.1016/s0828-282x(07)70765-1.
7
Health-related quality of life in cardiac patients with dyslipidemia and hypertension.合并血脂异常和高血压的心脏病患者的健康相关生活质量
Qual Life Res. 2004 May;13(4):793-804. doi: 10.1023/B:QURE.0000021695.26201.a0.
8
The postprandial effects of dietary antioxidants in humans.膳食抗氧化剂对人体的餐后影响。
Curr Atheroscler Rep. 2003 Nov;5(6):452-8. doi: 10.1007/s11883-003-0035-9.
9
A randomized controlled trial of an extensive lifestyle management intervention (ELMI) following cardiac rehabilitation: study design and baseline data.心脏康复后广泛生活方式管理干预(ELMI)的随机对照试验:研究设计与基线数据
Curr Control Trials Cardiovasc Med. 2002 Nov 12;3(1):9. doi: 10.1186/1468-6708-3-9.
10
Family history and the risk of coronary heart disease: comparing predictive models.家族病史与冠心病风险:预测模型比较
Eur J Epidemiol. 2001;17(7):609-20. doi: 10.1023/a:1015587428172.